Fig. 7

ZNF498 suppresses apoptosis and ferroptosis via p53 Ser46 phosphorylation-mediated p53 transcriptional activation. A HepG2 and Hep3B cells were transfected with the indicated plasmids for 36 h and collected for Western blotting. B HepG2 and Hep3B cells were transfected with the indicated siRNA or plasmids for 36 h and collected for apoptosis detection. C HepG2 and p53-knockout HepG2 cells were transfected with ZNF498 expression plasmid and treated with or without erastin (10 μM) for 24 h. The level of MDA was measured using a lipid peroxidation assay kit. D Cell viability was determined by CCK-8 assays in HepG2 and p53-knockout HepG2 cells transfected with ZNF498 expression plasmid and treated with or without erastin (40 μM) for 48 h. E p53-knockout HepG2 cells were transfected and treated as indicated, and GLS2 mRNA levels were analyzed by qPCR. F HepG2 cells were transfected as indicated and treated with Nutlin-3 (20 μmol/L) with or without cell death inhibitors (Fer-1, 2 μmol/L; ZVAD-FMK, 2 μmol/L) for 24 h, and cell viability was assayed. G Hep3B cells were transfected with plasmids as indicated for 48 h and subjected to qPCR to determine Puma mRNA levels. H Hep3B cells were transfected with the indicated plasmids and collected for apoptosis detection. I, J p53-knockout HepG2 cells were transfected with the indicated plasmids, treated with erastin (10 μM) for 24 h, and processed to detect MDA levels (I) and cell viability (J). K p53-knockout HepG2 cells were transfected with the indicated plasmids, and cell proliferation was measured using a CCK-8 assay. n = 3; ns, no significance; *P < 0.05; **P < 0.01